Last update 08 Feb 2025

NN-3201

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
NN-3201
Target
Tubulin x c-Kit
Mechanism
Tubulin inhibitors, c-Kit inhibitors(Stem cell growth factor receptor inhibitors)
Therapeutic Areas
NeoplasmsDigestive System DisordersEye Diseases+ [5]
Active Indication
Adenoid Cystic CarcinomaGastrointestinal Stromal TumorsRenal Cell Carcinoma+ [4]
Inactive Indication-
Originator Organization
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
Active Organization
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC39H67N5O7
InChIKeyDASWEROEPLKSEI-UIJRFTGLSA-N
CAS Registry474645-27-7

Related

1
Clinical Trials associated with NN-3201
NCT06805825
/ Not yet recruitingPhase 1
A Phase 1 Dose Escalation and Expansion Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects with Advanced And/or Metastatic Solid Tumors Known to Express C-Kit
100 Clinical Results associated with NN-3201
Login to view more data
100 Translational Medicine associated with NN-3201
Login to view more data
100 Patents (Medical) associated with NN-3201
Login to view more data
100 Deals associated with NN-3201
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenoid Cystic CarcinomaPhase 1
US
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
28 Feb 2025
Renal Cell CarcinomaPhase 1
US
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
28 Feb 2025
Uveal MelanomaPhase 1
US
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
28 Feb 2025
Gastrointestinal Stromal TumorsPhase 1
US
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
28 Feb 2025
Small Cell Lung CancerPhase 1
US
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
28 Feb 2025
Acute Myeloid LeukemiaPreclinical
KR
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
27 Jul 2022
Philadelphia chromosome positive chronic myelogenous leukemiaPreclinical
KR
Novelty Nobility, Inc.Novelty Nobility, Inc.Startup
27 Jul 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free